Novo Holdings Morphic Holding, Inc. Transaction History

Novo Holdings

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$26.12 - $34.07 $9.8 Million - $12.8 Million	375,000 New	375,000 $12.8 Million
Q2 2022 Aug 15, 2022	SELL	$19.74 - $43.01 $21.1 Million - $46 Million	-1,069,574 Reduced 65.42%	565,237 $12.3 Million
Q1 2022 May 16, 2022	SELL	$36.25 - $52.02 $15.1 Million - $21.6 Million	-415,635 Reduced 20.27%	1,634,811 $65.6 Million
Q3 2021 Nov 15, 2021	SELL	$53.61 - $67.5 $31.9 Million - $40.2 Million	-595,000 Reduced 22.49%	2,050,446 $116 Million
Q2 2019 Aug 14, 2019	BUY	$18.0 - $19.82 $47.6 Million - $52.4 Million	2,645,446 New	2,645,446 $52.4 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

Stay updated on Novo Holdings with notifications on news.